Navigation Links
NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance
Date:12/29/2008

SALT LAKE CITY, Dec. 29 /PRNewswire-FirstCall/ --Dynatronics Corporation (Nasdaq: DYNT) today announced that a second temporary grace period extension, filed by NASDAQ with the SEC, gives the company until approximately June 28, 2009, to comply with NASDAQ's $1 per share minimum bid rule.

"We are pleased that NASDAQ has further extended the timeframe for compliance in light of the current market environment," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "This will give us time to realize the impact of operating improvements that are emerging in part because of our recent agreement with Vici Capital, a private operations consulting firm that is assisting Dynatronics in identifying significant changes that we can implement to improve our bottom line over the next year."

In addition, Dynatronics' newly expanded catalog released in September is positively impacting sales, generating improved margins through adjusted product pricing.

"We are also facilitating greater order flow from our domestic dealers through an adaptation of our DynaClub direct sales program. This promises to be a source of increased revenue over the coming year as dealers embrace the benefits of this program," Cullimore continued. "We believe all of these improvements, together with the more than $2 million in annual expense reductions we have previously implemented, should restore profitability and build investor confidence in owning our stock."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and include specifically the reference in this press release to increased revenues through the DynaClub direct sales program and the reference to restoring profitability. Such statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2008.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
2. Memory Pharmaceuticals Regains Compliance with NASDAQ Market Capitalization Requirement
3. Mylan Announces Move to NASDAQ Stock Market
4. DATATRAK International, Inc. Receives Notice from NASDAQ
5. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
6. Memory Pharmaceuticals Receives NASDAQ Decisions
7. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
10. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
11. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: